Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome
Aim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At b...
Main Authors: | O. N. Andreeva, I. M. Korochkin, N. P. Rechnova, V. Yu. Pibovarov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2005-06-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/968 |
Similar Items
-
METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
by: M. E. Statsenko, et al.
Published: (2015-09-01) -
Metabolic (cytoprotective) therapy of menopausal disturbances
by: S. N. Tolstov, et al.
Published: (2011-06-01) -
Fixed dose combination of perindopril with indapamide in primary prevention of cerebrovascular complications among patients with metabolic syndrome and arterial hypertension
by: V. B. Mychka, et al.
Published: (2006-02-01) -
Clinical application of direct renin inhibitor aliskiren in combined therapy of patients with arterial hypertension and metabolic syndrome
by: O V Dralova, et al.
Published: (2010-12-01) -
THE COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL VALSARTAN AS A MONOTHERAPY OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE AND BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREE AND METABOLIC SYNDROME
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)